Abstract
Background
We sought to determine if IV tPA use for acute ischemic stroke (AIS) increased in Massachusetts in association with the Primary Stroke Service (PSS) program, a statewide stroke center designation and quality improvement (QI) initiative.
Methods and Results
We analyzed prospectively acquired data from the Massachusetts Department of Public Health (DPH) between October 2004 and June 2008 including 10,045 consecutive ED-based AIS encounters arriving ≤3 hrs after stroke onset at 69 participating Massachusetts PSS hospitals. The overall rate of IV tPA use was 854/3866 (22.1%) of patients arriving ≤2 hours of symptom onset. IV tPA use increased steadily from 2005 (the first full year of the program) to 2008 (18.4%, 21.9%, 22.6%, 25.5%, p=0.001). Patients treated with IV tPA were more likely to be younger (72.3±14.1 vs. 74.7±14.0, p<0.005) and to have presented after EMS re-routing in July 2005 (96% vs. 94%, p=0.009). Patients who arrived at hospitals with a performance achievement award from the Get With The Guidelines-Stroke program were more likely to receive IV tPA after vs. before award recognition (28.1% vs. 22.3%, p<0.001).
Conclusions
In this nearly complete capture of statewide data, rates of IV tPA improved significantly in Massachusetts from 2005 to 2008 in association with a state PSS designation program. Further studies are needed to confirm that treatment disparities exist for older AIS patients, and that the rates of thrombolysis have increased above and beyond secular trends.
Keywords: acute stroke, quality improvement, stroke management, thrombolysis
Introduction
Intravenous tPA improves outcomes in patients with acute ischemic stroke (AIS);1 however, only a small proportion of eligible patients actually receive this treatment.2, 3 Delay in patient arrival4 and inadequate hospital infrastructure or support5 contribute to low treatment rates. Multiple quality improvement (QI) initiatives aimed at improvement of AIS care have been implemented over the past decade to increase treatment rates, including the Centers for Disease Control and Prevention’s Paul Coverdell National Acute Stroke Registry (PCNASR),6 the American Heart Association (AHA)’s Get-With the Guideline-Stroke (GWTG-S) program,7, 8 state-based stroke center designation programs,5 and reorganization of emergency medical services (EMS) to screen for stroke symptoms and triage patients to stroke centers with pre-arrival notification.9, 10
In Massachusetts (MA), broad hospital participation in the PCNASR and GWTG-S played a major role in setting the standards for acute stroke care. The PCNASR, a state-based stroke QI registry, began by supporting development of a set of prototype registries in 2001. The initial PCNASR prototype in MA was the creation and implementation of the GWTG-S pilot. Since that time, the AHA and MA Department of Public Health (DPH) have been partners in the PCNASR implementation in MA.
Primary Stroke Service (PSS) designation was implemented by the MA DPH to facilitate the preparedness of each individual hospital for treatment of AIS patients, and by December 2005, 92% of MA hospitals achieved PSS designation based on documented demonstration of care protocols for AIS.11–14 The PSS program was based on the acute phase of the Brain Attack Coalition criteria, such that all PSS hospitals were required to document access to acute stroke teams, 24-hour rapid computer tomography (CT) or MR scanning and interpretation, access to neurosurgery coverage ≤2 hours of request (including by inter-facility transfer), mandatory data collection in a stroke registry, performance review with local quality initiatives, community education and an on-site verification by DPH personnel.11, 15
We sought to determine factors predictive of changing rates of tPA treatment in MA from 2004–2008.
Methods
Program Description and Quality of Care Definitions
To increase the quality of AIS care provided in MA hospitals, including perceived geographic disparities in the rates of thrombolysis, the MA PSS Designation program was conceived in 2003 and implemented in 2005. All non-Federal MA acute care hospitals were eligible to participate. To be licensed as a PSS, hospitals were required to meet modified Brain Attack Coalition criteria relevant to emergency stroke care including (a) presence and availability of experienced acute stroke team, (b) emergency department (ED) experience in acute stroke, (c) 24-hour availability of rapid CT scanning and interpretation, (d) 24-hour availability of laboratory diagnostic testing, (e) availability of neurosurgical services ≤2 hours or request, (f) presence of written and annually reviewed stroke care pathways, (g) quality review and performance improvement activities including stroke registry, and (h) provision for continuing education in stroke.11–14
All participating hospitals submitted applications with documentation of the required hospital resources, and the DPH personnel verified the presence of these resources by on-site inspection. Maintenance of PSS status is dependent on mandatory data reporting of all AIS patients who present ≤3 hours of last seen well (LSW), with receipt of data on each AIS patient within 2 months of discharge. Periodic on-site surveys have been conducted in response to complaints, serious incidents, certain negative data outliers, and all sites were recently revisited in 2010 for a re-licensure assessment.
Sixty-nine out of 70 acute care hospitals in MA ultimately achieved state PSS designation. The single non-participating hospital was a very small rural hospital with the lowest AIS volume in the state (10 IV tPA cases between 2002–2010). Hospitals joined the program in a rolling fashion: 4 hospitals were designated PSS in 2004, 63 hospitals in 2005, and 2 hospitals in 2007. No hospitals has subsequently dropped out of the program or failed to achieve re-licensure.
Beginning in July 2005, the MA DPH mandated transport of suspected acute AIS patients to the nearest designated PSS hospital, potentially bypassing nearer facilities, for patients with symptom duration ≤2 hours.16
Many hospitals also simultaneously participated in GWTG-S, a prospective, nonrandomized, national, AHA-sponsored QI stroke program that was designed and implemented in MA in 2001 and nationwide as of April 2004. At each hospital, trained personnel are instructed to use GWTG-S to collect data on consecutive patients admitted to the hospital with a principal clinical diagnosis of stroke or transient ischemic attack (TIA). Hospitals upload data via a web-based tool and can download on-demand reports of adherence on a variety of stroke measures, including all of the stroke measures endorsed by the National Qualify Forum (NQF)7 as well a series of additional quality, reporting, and demographic information. The provision of IV tPA to eligible patients presenting ≤2 hours of LSW time is one of these NQF-endorsed stroke measures. Hospitals that demonstrate ≥85% adherence on seven stroke “achievement measures” (those judged to be of highest scientific evidence) over 12 months are recognized with an achievement award.7 The seven GWTG-S achievement measures are antithrombotics within 48 hours, antithrombotics at discharge, IV tPA in eligible patients ≤2 hours, DVT prophylaxis by day 2, warfarin for atrial fibrillation, statin therapy at discharge if LDL >100 mg/dL and smoking cessation therapy (Table 1). All of these measures are NQF-endorsed stroke measures with the exception of smoking cessation therapy, which is not specifically endorsed for stroke but is endorsed by the NQF as a global inpatient measure. Two NQF-endorsed stroke measures, stroke education and assessment for rehabilitation, are included in GWTG-S but as “quality measures” that do not count toward performance achievement awards. Additional components of GWTG-S include organizational stakeholder and opinion leader meetings, prospective recruitment, collaborative workshops for hospital teams, hospital tool kits, and hospital recognition.7
Table 1.
Quality Indicator Comparison | TJC PSS | GWTG |
---|---|---|
IV-tPA in eligible patients | ✓* | ✓+ |
DVT prophylaxis by day 2 | ✓* | ✓+ |
Warfarin for patients with atrial fibrillation | ✓* | ✓+ |
Antithrombotics at discharge | ✓* | ✓+ |
Antithrombotics within 48 hours | ✓* | ✓+ |
Dysphagia screen by day 2 | ✓ | |
Smoking cessation | ✓ | ✓+ |
Stroke education | ✓* | |
Assessed for rehabilitation | ✓* | |
Statin at discharge if LDL >100 | ✓* | ✓+ |
Indicates NQF endorsement;
indicates part of GWTG performance achievement award;
indicates collected as part of the quality program
Study Population and Measurements
We conducted a retrospective review of data collected on patients diagnosed with AIS based on the MA DPH PSS records between October 2004 and June 2008. Most sites used a combination of prospective ascertainment and retrospective data collection. The DPH did not formally audit data entry against medical records, although DPH onsite visits for certification were performed twice at each hospital, and more frequently if routine DPH monthly data analyses identify outlier behavior in rates of treatment, interval between last record entered, and overall case volumes.
Mandatory data reporting as part of PSS designation included collecting and entering online the following data on all patients with a final clinical diagnosis of ischemic stroke who arrive ≤3 hours of LSW time: location when stroke occurred, age, race/ethnicity, gender, time of LSW and symptom discovery, time of ED arrival, time of first brain imaging study initiated, time of tPA administration or reason for non-treatment, complications after tPA, date of restricting care to “comfort only” if performed, and discharge destination including mortality. Web-based Coding instructions,13 data collection form,12 and application materials14 are available online to hospitals.
Hospital data included number of beds and all admitted patients as assessed by the annual hospital-specific discharge data. The MA DPH provided information that 56 hospitals participated in the PCNASR in 2007. However, actual dates and duration of participation for each hospital from 2005 to 2008 were lacking, therefore PCNASR participation could not be included as a variable in patient-level analyses, because it was not certain whether the patient was admitted during a time of active participation or not. Information on the Joint Commission (TJC) Stroke Center certification was not available. AIS-related discharges were based on mandatory data reporting by the hospitals, which included all AIS cases that present with symptoms ≤3 hours of onset, regardless of whether or not they are eligible for IV tPA.
Statistical Methods
Characteristics of patients who did or did not receive IV tPA were tabulated and displayed as either means or percentages. Logistic regression was used to determine whether patient characteristics were associated with the probability of receiving IV tPA, using generalized estimating equations with an exchangeable working correlation matrix to account for the clustering of patients within hospitals. A test of linear trend was used for ordinal categorical variables such as discharge year. A multivariable logistic regression model was used to identify independent predictors of IV tPA use. Candidate predictors were based on clinical plausibility as well as results of unvariate testing. Univariate analyses showed an approximately linear relationship between the odds of tPA use and discharge year but a non-linear relationship between the odds of tPA use and age and hospital bed size. Therefore discharge year was entered into the model as a continuous variable while age and hospital bed size were entered as categorical variables--age categories were <80, 80–89 and ≥90, while bed size was analyzed as the top quartile (largest bed size) compared to the lower three quartiles. The age category cut-offs were selected a priori based on previously published studies.17–19 Statistical significance level for all analyses was set at p < 0.05. Analyses were performed using SAS version 9.2 (Cary, NC).
Results
There were 10,983 AIS patient admissions during the study period. Excluded from analysis were: 546 (4.9%) in-patient strokes, 4 (0.03%) patients aged < 18 years, 37 (0.3%) patients who received IV tPA at another hospital, 25 (0.02%) with missing information on critical variables (age, IV tPA use or discharge destination), and 306 (2.8%) patients with coding errors.
Between 2005–2008, there was a steady increase per year in the proportion of patients arriving ≤2 hours of AIS onset in the PSS database (36.3% in 2005 vs. 40.7% in 2008, p<0.001) (Table 2). The proportion of patients arriving ≤2 hours and treated with IV tPA, expressed as a percentage of all stroke patients, increased from 6.7% in 2005 to 10.4% in 2008 (p=0.006). Among the patients who arrived ≤2 hours after stroke onset, the proportion treated with IV tPA increased from 18.4% in 2005 to 25.5% in 2008 (p=0.002)(Table 2).
Table 2.
DISCHARGE YEAR | Total discharges | Arrival in ≤2 hours | Arrived ≤2 hours and treated with IV tPA | ||||
---|---|---|---|---|---|---|---|
Number | Percent | Number | % of total discharges | Number | % of all ≤120min | % of total discharges | |
2004 | 38 | 0.38 | 13 | 34.2 | 3 | 23.1 | 7.9 |
2005 | 1904 | 18.95 | 692 | 36.3 | 127 | 18.4 | 6.7 |
2006 | 3153 | 31.39 | 1253 | 39.7 | 274 | 21.9 | 8.7 |
2007 | 3382 | 33.67 | 1270 | 37.6 | 287 | 22.6 | 8.5 |
20081 | 1568 | 15.61 | 638 | 40.7 | 163 | 25.5 | 10.4 |
total | 10045 | 100 | 3866 | 38.5 | 854 | 22.1 | 8.5 |
Represents data from the first half of 2008 (January to June) only.
Abbreviations: IV tPA - intravenous thrombolysis with tissue plasminogen activator, PSS – primary stroke service
Table 3 shows hospital data as well as patient characteristics and outcomes in the 10,045 patients with AIS. Of the 10,045 patients, 3866 (38.5%) presented to the ED ≤2 hours from symptom onset, and 854/3866 (22.1%) received IV tPA treatment. Characteristics associated with IV tPA use in patients arriving ≤2 hours included younger age (p<0.001), discharge year (p=0.002), presenting with AIS symptoms after the EMS re-routing was implemented (p<0.009), and presenting to a hospital that received a GWTG-S recognition award (p<0.001) (Table 4). There was a trend toward an association between larger hospital bed size and an increased likelihood of IV tPA treatment (p=0.08).
Table 3.
Total N=10045 | |
---|---|
Patient Characteristics and Outcomes | |
Age,* yrs | 74.9 (13.7) |
Female, n (%) | 5505 (54.8) |
Race/Ethnicity, n (%) | |
White | 8795 (87.6) |
Black | 516 (5.1) |
Hispanic (any race) | 293 (2.9) |
Symptom duration,*# mins | 129 (56, 720) |
Patient arrival via EMS, n (%) | 7322 (73.2) |
IV tPA administered, n (%) | 946 (9.42) |
Thrombolytic complications, n (%) | 58/946 (6.1) |
Discharged to home n (%), | 3463 (34.5) |
Died or discharged to hospice, n (%) | 951 (9.5) |
Hospital-Level Data | |
Number of beds* | 152 (105–225) |
Number of patients* | 53 (23–75) |
Percent of patients arriving ≤2 hours treated with IV tPA | 20% (13%, 32%) |
expressed as mean (standard deviation) or median (interquartile range)
time from onset to ED arrival
Abbreviations: ED – emergency department, EMS – emergency medical services, min – minutes, IV tPA – intravenous thrombolysis with tissue plasminogen activator
Table 4.
Characteristic | IV tPA (n=854) | No IV tPA (n=3,012) | P value |
---|---|---|---|
Age, mean (SD) | 72.3 (14.1) | 74.7 (14.0) | 0.005 |
Age | <0.001 | ||
<80 years | 63% | 55% | |
80–89 years | 30% | 33% | |
≥90 years | 7% | 11% | |
Female | 51% | 52% | 0.67 |
Non-white race | 12% | 11% | 0.63 |
Discharge year | 0.002 | ||
2004 | 0.4% | 0.3% | |
2005 | 15% | 19% | |
2006 | 32% | 33% | |
2007 | 34% | 33% | |
2008 | 19% | 16% | |
After EMS re-routing began | 96% | 94% | 0.009 |
Presented to hospital with GWTG award | 32% | 20% | <0.001 |
Presented to hospital with televideo consultation | 16% | 18% | 0.95 |
Number of beds, median (IQR) | 223 (132–311) | 205 (132–284) | 0.08 |
Bed quartile | 0.84 | ||
1st quartile (19–126 beds) | 23% | 24% | |
2nd quartile (132–192 beds) | 20% | 21% | |
3rd quartile (194–264 beds) | 21% | 26% | |
4th quartile (272–902 beds) | 35% | 28% | |
Presented to rural hospital ED | 11% | 12% | 0.79 |
Presented to teaching hospital ED | 41% | 34% | 0.35 |
Table percentages represent column percentages. Significance testing is by univariate logistic regression using generalized estimating equations with an exchangeable working correlation matrix to account for clustering of patients within hospitals. A linear trend test was used for ordinal categorical variables (age categories, discharge year and bed quartiles).
Abbreviations: ED – emergency department, EMS – emergency medical services, GWTG - Get With The Guidelines initiative, MA – Massachusetts, PSS – primary stroke service, SD – standard deviation, tPA – intravenous thrombolysis
In multivariable analysis, age over 80 years independently decreased the odds of having IV tPA treatment in those patients who presented ≤2 hours of their AIS symptoms and who were aged 80–89 (OR 0.8, 95%CI 0.7–0.9) as well as those 90 years and above (OR 0.6, 95%CI 0.4–0.8). There was a trend toward an increased rate of IV tPA use in patients transported after EMS re-routing began, but the effect was not significant (OR 1.5, 95%CI 0.9–2.2). Larger hospital bed size was not associated with a greater likelihood of IV tPA use after controlling for other variables. Presenting to a hospital later within the study period independently increased the odds of being treated with IV tPA (OR 1.1 per each additional year, 95% CI 1.03–1.2) (Table 5).
Table 5.
Characteristic | OR | 95% CI | P value |
---|---|---|---|
Age * | |||
80–89 years | 0.8 | 0.7–0.9 | 0.007 |
≥90 years | 0.6 | 0.4–0.8 | 0.002 |
Discharge year (per year) | 1.1 | 1.03–1.2 | 0.01 |
Discharge after EMS re-routing | 1.5 | 0.9–2.2 | 0.08 |
Presented to hospital with telemedicine-enabled consultation | 0.9 | 0.6–1.3 | 0.61 |
Number of beds (median) | 1.2 | 0.8–1.8 | 0.28 |
Admitted to teaching hospital | 1.0 | 0.7–1.6 | 0.85 |
Candidate variables were all those associated with IV tPA use in the univariate analysis with p<0.15
compared with reference tertile (age< 80 years)
Abbreviations: EMS – emergency medical services, MA – Massachusetts, PSS – primary stroke service, IV tPA – intravenous thrombolysis with tissue plasminogen activator
There were 29 hospitals that received a GWTG-S achievement award during the study period. Whereas characteristics of the award hospitals varied broadly, when compared to those without awards, awards hospitals were larger (p=0.02), less likely to participate in televideo consultation (p=0.04), more likely to be teaching hospitals (p<0.001), and more likely to be a participant in the PCNASR (p=0.009). Patients seen at a hospital with an achievement award were more likely to receive IV tPA (Table 4). When we restricted the analysis to the 28 hospitals that received a GWTG-S achievement award during the study period, (excluding 1 hospital with award recognition prior to PSS designation), the rate of IV tPA was higher after compared with before award recognition (28.1% vs. 22.3%; p=0.002). When award status was added to the multivariable model described previously (shown in Table 5), award status was independently associated with IV tPA use (adjusted OR 1.4, 95% CI 1.1–1.7) while the effect of calendar year was no longer significant.
Discussion
This review of statewide data from MA demonstrates a substantially higher rate of IV tPA use than previously reported in nationwide datasets,3 including those reported concurrently with our study timeline.20 Additionally, the rate of IV tPA use increased significantly from 2004 to 2008 in conjunction with a state designation program for PSS coupled with a national quality improvement program. These data support the ongoing efforts to implement stroke QI initiatives nationwide in order to increase the use of IV tPA and adherence to evidence based AIS care.
The PSS program launched in MA in 2004 at roughly the same time as the original pilot of TJC PSC program. At its inception, the PSC program was focused on rates of “IV tPA considered” rather than the rate of tPA administered and did not require mandatory data reporting. There was a strong feeling in MA of the need for state level data collection and reporting on acute stroke care. For both of these reasons, the MA DPH proceeded with the PSS offering, which was rapidly adopted by MA hospitals. Since there is significant overlap with the PSC program, and the PSS program was offered at a very low cost to sites, few MA hospitals chose to seek the additional certification and costs necessary for PSC status. However it is likely that the rapid pace of adoption of the PSC program nationally drove MA hospitals to join some form of stroke center certification program, and they by and large chose PSS. Of the 69 PSS hospitals in the program during 2004–2008, 29/69 (42%) received an award from the AHA GWTG-S program for providing each of the achievement measure interventions for which they were eligible to ≥85% of GWTG-S patients, including IV tPA for those arriving ≤2 hours of onset.
PSS hospitals in the state of MA vary greatly in their characteristics, and in particular, their size, location, and affiliations. Despite the differences, they were all subject to the same DPH requirements;11 and therefore, all had to acquire resources necessary for provision of AIS care. Despite initial limitations, hospitals found solutions to existing barriers, including innovative strategies such as access to telemedicine consultations and inter-facility transfer agreements. While larger hospitals were more likely to be early adopters of the PSS program and more likely to provide IV tPA, this effect was mitigated when the GWTG-S award status was included in the model. This effect suggests that the award reflects actual increased rates of treatment with IV tPA (rather than simply documenting more contraindications), and that hospitals both large and small are able to achieve increased levels of IV tPA use.
Prior studies have indicated that statewide initiatives can improve quality outcomes;5 however, whereas the implementation of the regional systems of care is feasible, its effectiveness is still being elucidated.21 The MA data from 2004 to 2008 show a relatively high and increasing rate of IV tPA use compared to nationwide data, stroke registries, and nearby states. Administrative data from the Nationwide Inpatient Sample suggest that the overall IV tPA treatment rate among all AIS patients was 1% in 1999–200222 and had only increased to 3.4% by 2009.23 In the PCNSAR, pilot projects demonstrated that the rate of IV tPA use ranged from 2.7% to 8.5% across the pilot states, while the data from 2005–2007 showed that 3.6% of patients received IV tPA. Among the patients arriving ≤2 hours in the PCNASR from 2005–2007, 20.6% received IV tPA. Data from the national GWTG-S program show that 16.0% of patients arriving ≤2 hours were treated with IV tPA in 2005, compared to 27.2% in 2008.24
Statewide longitudinal data over time are mostly lacking; however, a recent study from New York state showed that IV tPA was given to 3.2% of ischemic stroke patients overall in 2005 and 2006, including to 4.8% of the patients admitted to state-designated stroke centers and 1.7% of the patients admitted to non-stroke centers. By comparison, the MA rate of IV tPA utilization in PSS hospitals increased from 6.7% to 10.4% of all ischemic strokes between 2005 to 2008, or 18.4% to 25.5% when expressed as a percentage of all AIS patients arriving ≤2 hours.
The MA rates exceed those observed in the national and New York-based studies, and compare favorably to the rates of increase seen in the selected hospital populations participating in the PCNSAR and GWTG-S quality improvement initiatives, suggesting that the state-based program has been effective in encouraging IV tPA use in excess of national secular trends. The potential influence on the observed rate increase in IV tPA administration of other concomitant statewide QI initiatives adopted during the study period is difficult to ascertain, in large part because they share many common aspects. In Massachusetts, participation in the initial PCNASR phase that focused on performance measures and data element creation contributed fundamentally to development and statewide implementation of the AHA GWTG-Stroke pilot in 2001. Furthermore, the implementation of the Massachusetts CDC-funded Paul Coverdell Registry was done in partnership between the MA DPH and the AHA, and the in-hospital stroke QI initiative was renamed the “Stroke Collaborative Reaching for Excellence” (SCORE) program. The joint program uses the GWTG data platform to collect and report hospital data and performance to participating hospitals and to the state with the goal of creating a sustainable data-driven stroke QI collaborative that would further facilitate statewide efforts of stroke care QI through hospital-level policy and system change (http://www.scorema.org/index.html). To date, SCORE has utilized significant state resources to provide a number of training opportunities in order for participating hospitals to improve quality of stroke care. All hospitals enrolled in SCORE were PSS designated, and used again the same data platform to report the PSS required elements to the MA DPH. In summary, it is quite likely that the effects of participation in these multiple coordinated statewide and nationwide programs is additive in MA. A different study design with control hospitals would be required to elucidate the differential impact of each initiative and is beyond the scope of this dataset.
The GWTG-S program is a voluntary, nationwide QI initiative8 that showed consistently the benefits of prospective surveillance of patient care in stroke.7, 8 Hospitals seeking GWTG-S award are subject to continuous commitment to excellence and improvement of, at minimum, inpatient quality of care for patients with stroke, as based on the defined performance and safety measures.7 It may be that hospitals receiving award status were those sites most highly motivated to improve, and that the specific stroke measures selected may have been less important than the organized award program itself. Ongoing efforts by the AHA to improve hospitals’ ability to treat eligible patients with IV tPA within 60 minutes of ED arrival may help identify hospital-level factors that are associated with high performing sites, and lend further insights into the role of award status (www.heart.org/targetstroke).
Nationwide QI initiatives such as GWTG-S, allows hospitals to focus on multiple aspects of inpatient stroke care and through the accumulated data of this large, representative program, trends in care and improvement in patients with stroke in the United States are being explored.25–27 Given the urgency of acute thrombolysis in AIS,28, 29 improving pre-hospital systems of care for AIS patients has proven to be a powerful method to decrease delays in ED arrival.9, 30, 31 In MA, EMS re-routing was implemented as part of the DPH PSS Program to improve AIS patient access to the PSS-designated hospitals to facilitate acute thrombolysis. These measures, along with other statewide QI initiatives such as pre-arrival hospital notification by EMS in AIS expedite the treatment timeline,10 which is crucial to the overall improvement in outcomes.32
In our study, implementation of the EMS re-routing improved the odds of AIS being treated with IV tPA; however, this association did not remain significant when other independent predictors of thrombolysis were considered. Our data suggest that a plan for EMS re-routing may be effective in increasing IV tPA use, but may not have been statistically significant because we had so few patients entered in the database before re-routing began. The EMS bypass policy itself probably encouraged rapid adoption of the PSS program. It was initiated shortly after PSS designation began, resulting in few patients being admitted to PSS designated hospitals before the bypass policy came into effect. It is also possible that other factors such as age, hospital characteristics or other confounders may have contributed to the loss of significance of the EMS bypass model term.
Patient advancing age is consistently associated with reduced rates of thrombolysis.27 Despite a lack of evidence that older patients are harmed by thrombolysis,17, 18 and the fact that advanced age is a relative rather than absolute contraindication to IV tPA, many centers offer IV tPA less frequently to older patients.1, 33 The relationship between older age and decreased odds of thrombolysis is difficult to examine due to variations in interpretation and implementation of age-based restrictions on thrombolysis at the provider or hospital level.8 In our statewide sample, the odds of being treated with IV tPA decreased steadily by decade of age, as compared to the younger patients (<80 years at the time of their AIS). Local, regional, and nationwide acute stroke care may benefit in the future from prospective observations made in the comprehensive databases such as GWTG-S in order to overcome perceived obstacles to high quality of care in the elderly, who are the majority of AIS victims.7, 34
This study has several limitations. The data collection method in this study is based on site-level retrospective chart review by a trained data abstractor and therefore depends on the accuracy and reliability of chart documentation, and the quality of abstraction. However, a recent data audit by the MA DPH of 78 variables in 1300 patient records at 58 PSS hospitals that are part of the CDC PCNASR and AHA GWTG-S found very high rates of data quality.35 In addition, the required data reporting is part of the state PSS designation; therefore we do not have data from hospitals prior to their PSS participation, and due to nearly 100% participation there is no comparison group. We do not have information on TJC Stroke Center certification. However, we anticipate that the effect of participation in each specific QI will be difficult to partition due to the high degree of overlap between the programs at each individual hospital, as was seen in this study with regard to GWTG award recognition and PCNASR program participation. Other larger studies with information on state-based, TJC, PCNASR, and GWTG-S participation will be needed to fully elucidate the independent effects of each program. We cannot exclude that some of the improvements in IV tPA use were related to secular trends and not the PSS stroke center designation program itself. However, even among the PSS hospitals we found a further increase in rates of IV tPA use among hospitals that earned a GWTG-S achievement award, suggesting that QI programs did have an effect on rates of IV tPA delivery.
One advantage of our analysis is the nearly complete data capture from a geographically defined region, with lack of data from only the single smallest hospital in the state. Our findings suggest that IV tPA rates may have increased substantially since early studies showed little adoption of IV tPA for AIS at a nationwide level. Further studies will be needed to identify national and regional trends in IV tPA use and barriers to use. In summary, review of this state-wide AIS dataset of early arriving patients demonstrates that successful participation in local and national QI initiatives such as GWTG-S and statewide stroke systems of care implementation that includes EMS rerouting had significant impact on the rates of thrombolysis for AIS in the state of MA. These data support the ongoing state-based efforts to implement QI initiatives in the context of stroke systems of care in order to increase the use of IV tPA.
What is Known
IV tPA improves outcomes in patients with acute ischemic stroke; however, only a small proportion of eligible patients actually receive this treatment
Multiple quality improvement initiatives aimed at improvement of acute stroke care have been implemented over the past decade to increase treatment rates
What this Article Adds
This is the first report on changes in absolute rates of IV tPA treatment measured over time in a state-wide sample that includes all hospitals in the state
This report explores the relationship between the quality improvement award recognition and high absolute rates of tPA use for acute stroke
This unique state-wide sample analysis highlights the importance of public health initiatives in partnership with national quality improvement programs in the improvement of outcomes for stroke.
Acknowledgments
Funding sources: none
Footnotes
Disclosures:
Dr. Natalia Rost has nothing to disclose.
Dr. Eric Smith has nothing to disclose.
Dr. Muhammad A. Pervez has nothing to disclose.
Mr. Philip Mello is a quantitative analyst with the Massachusetts Department of Public Health.
Mr. Paul Dreyer is a former Director of the Bureau of Health Care Safety and Quality in the Massachusetts Department of Public Health.
Dr. Lee Schwamm serves as the chair of the GWTG National Steering Committee (unpaid), a member of the AHA Primary Stroke Center advisory committee (unpaid) and as a stroke systems consultant to the Department of Public Health in Massachusetts (paid).
Contributor Information
Natalia S. Rost, Stroke Service, Department of Neurology, Massachusetts General Hospital, Boston, MA.
Eric E. Smith, Stroke Service, Department of Neurology, Massachusetts General Hospital, Boston, MA.
Muhammad A. Pervez, Stroke Service, Department of Neurology, Massachusetts General Hospital, Boston, MA.
Philip Mello, Department of Public Health, Boston, MA.
Paul Dreyer, Department of Public Health, Boston, MA.
Lee H. Schwamm, Stroke Service, Department of Neurology, Massachusetts General Hospital, Boston, MA.
References
- 1.The National Institute of Neurological Disorders and Stroke rt PASSG. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 1995 Dec 14;333(24):1581–1588. doi: 10.1056/NEJM199512143332401. [DOI] [PubMed] [Google Scholar]
- 2.Rost NS, Masrur S, Pervez MA, et al. Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology. 2009 Dec 8;73(23):1957–1962. doi: 10.1212/WNL.0b013e3181c5b46d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bateman BT, Schumacher HC, Boden-Albala B, et al. Factors Associated With In-Hospital Mortality After Administration of Thrombolysis in Acute Ischemic Stroke Patients: An Analysis of the Nationwide Inpatient Sample 1999 to 2002. Stroke. 2006 Feb 1;37(2):440–446. doi: 10.1161/01.STR.0000199851.24668.f1. [DOI] [PubMed] [Google Scholar]
- 4.California Acute Stroke Pilot Registry I. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005 Feb 22;64(4):654–659. doi: 10.1212/01.WNL.0000151850.39648.51. [DOI] [PubMed] [Google Scholar]
- 5.Gropen TI, Gagliano PJ, Blake CA, et al. Quality improvement in acute stroke: The New York State Stroke Center Designation Project. Neurology. 2006 Jul 11;67(1):88–93. doi: 10.1212/01.wnl.0000223622.13641.6d. [DOI] [PubMed] [Google Scholar]
- 6.http://www.cdc.gov/DHDSP/stroke_registry.htm
- 7.Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack. Circulation. 2009 Jan 6;119(1):107–115. doi: 10.1161/CIRCULATIONAHA.108.783688. [DOI] [PubMed] [Google Scholar]
- 8.Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke. Circ Cardiovasc Qual Outcomes. 2010 Feb 22; doi: 10.1161/CIRCOUTCOMES.109.921858. CIRCOUTCOMES.109.921858. [DOI] [PubMed] [Google Scholar]
- 9.Acker JE, III, Pancioli AM, Crocco TJ, et al. Implementation Strategies for Emergency Medical Services Within Stroke Systems of Care: A Policy Statement From the American Heart Association/ American Stroke Association Expert Panel on Emergency Medical Services Systems and the Stroke Council. Stroke. 2007 Nov 1;38(11):3097–3115. doi: 10.1161/STROKEAHA.107.186094. [DOI] [PubMed] [Google Scholar]
- 10.Abdullah AR, Smith EE, Biddinger PD, et al. Advance Hospital Notification by EMS in Acute Stroke Is Associated with Shorter Door-to-Computed Tomography Time andIncreased Likelihood of Administration of Tissue-Plasminogen Activator. Prehospital Emergency Care. 2008;12(4):426–431. doi: 10.1080/10903120802290828. [DOI] [PubMed] [Google Scholar]
- 11.Smith EE, Dreyer P, Prvu-Bettger J, et al. Stroke Center Designation Can be Achieved by Small Hospitals: The Massachusetts Experience. Critical Pathways in Cardiology. 2008;7(3):173–177. doi: 10.1097/HPC.0b013e318184e2bc. 110.1097/HPC.1090b1013e318184e318182bc. [DOI] [PubMed] [Google Scholar]
- 12.http://www.mass.gov/Eeohhs2/docs/dph/quality/healthcare/stroke_data_form.pdf
- 13.http://www.mass.gov/Eeohhs2/docs/dph/quality/healthcare/stroke_data_instructions.pdf
- 14.http://www.mass.gov/Eeohhs2/docs/dph/quality/healthcare/stroke_service_materials_list.pdf
- 15.http://www.mass.gov/?pageID=eohhs2subtopic&L=7&L0=Home&L1=Provider&L2=Certification%2c+Licensure%2c+and+Registration&L3=Facilities&L4=Health+Care+Facilities+and+Programs&L5=Hospitals&L6=Stroke+Services&sid=Eeohhs2
- 16.http://www.mass.gov/Eeohhs2/docs/dph/emergency_services/ambulance_stroke_point_of_entry.pdf
- 17.Berrouschot J, Rother J, Glahn J, et al. Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (>=80 Years) Stroke Patients. Stroke. 2005 Nov 1;36(11):2421–2425. doi: 10.1161/01.STR.0000185696.73938.e0. [DOI] [PubMed] [Google Scholar]
- 18.Tanne D, Gorman MJ, Bates VE, et al. Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Patients Aged 80 Years and Older: The tPA Stroke Survey Experience. Stroke. 2000 Feb 1;31(2):370–375. doi: 10.1161/01.str.31.2.370. [DOI] [PubMed] [Google Scholar]
- 19.Mateen F, Nasser M, Spencer BR, Freeman WD, Shuaib A, Demaerschalk BM, Wijdicks EF. Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older. Mayo Clin Proc. 2009;84:334–338. doi: 10.1016/S0025-6196(11)60542-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.George MTX, McGruder H, Yoon P, Rosamond W, Winquist A, Hinchey J, Wall H, Pandey D. Paul Coverdell National Acute Stroke Registry Surveillance - Four States, 2005–2007. MMWR. 2009;58(SS-7):1–23. [PubMed] [Google Scholar]
- 21.Gropen T, Magdon-Ismail Z, Day D, et al. Regional Implementation of the Stroke Systems of Care Model: Recommendations of the Northeast Cerebrovascular Consortium. Stroke. 2009 May 1;40(5):1793–1802. doi: 10.1161/STROKEAHA.108.531053. [DOI] [PubMed] [Google Scholar]
- 22.Bateman BT, Schumacher HC, Boden-Albala B, et al. Factors Associated With In-Hospital Mortality After Administration of Thrombolysis in Acute Ischemic Stroke Patients. Stroke. 2006 Feb 1;37(2):440–446. doi: 10.1161/01.STR.0000199851.24668.f1. [DOI] [PubMed] [Google Scholar]
- 23.Adeoye O, Hornung R, Khatri P, et al. Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States. Stroke. 2011 Jul 1;42(7):1952–1955. doi: 10.1161/STROKEAHA.110.612358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Reeves MJ, Grau-Sepulveda MV, Fonarow GC, et al. Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? Circulation: Cardiovascular Quality and Outcomes. 2011 Sep 1;4(5):503–511. doi: 10.1161/CIRCOUTCOMES.111.961755. [DOI] [PubMed] [Google Scholar]
- 25.Reeves MJ, Vaidya RS, Fonarow GC, et al. Quality of Care and Outcomes in Patients With Diabetes Hospitalized With Ischemic Stroke: Findings From Get With the Guidelines-Stroke. Stroke. 2010 May 1;41(5):e409–417. doi: 10.1161/STROKEAHA.109.572693. [DOI] [PubMed] [Google Scholar]
- 26.Reeves MJ, Fonarow GC, Zhao X, et al. Quality of Care in Women With Ischemic Stroke in the GWTG Program. Stroke. 2009 Apr 1;40(4):1127–1133. doi: 10.1161/STROKEAHA.108.543157. [DOI] [PubMed] [Google Scholar]
- 27.Fonarow GC, Reeves MJ, Zhao X, et al. Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients With Ischemic Stroke. Circulation. 2010 Feb 23;121(7):879–891. doi: 10.1161/CIRCULATIONAHA.109.892497. [DOI] [PubMed] [Google Scholar]
- 28.Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. The Lancet. 2010 May 21;375(9727):1695. doi: 10.1016/S0140-6736(10)60491-6. [DOI] [PubMed] [Google Scholar]
- 29.Lyden PD. Extending the time window for thrombolytic therapy--primum non tardare. The Lancet Neurology. 2009;8(12):1074. doi: 10.1016/S1474-4422(09)70274-1. [DOI] [PubMed] [Google Scholar]
- 30.Rajajee V, Saver J. Prehospital Care of the Acute Stroke Patient. Techniques in Vascular and Interventional Radiology. 2005;8(2):74. doi: 10.1053/j.tvir.2005.03.004. [DOI] [PubMed] [Google Scholar]
- 31.Gladstone DJ, Rodan LH, Sahlas DJ, et al. A Citywide Prehospital Protocol Increases Access to Stroke Thrombolysis in Toronto. Stroke. 2009 Dec 1;40(12):3841–3844. doi: 10.1161/STROKEAHA.108.540377. [DOI] [PubMed] [Google Scholar]
- 32.Lyden P. Thrombolytic Therapy for Acute Stroke -- Not a Moment to Lose. N Engl J Med. 2008 Sep 25;359(13):1393–1395. doi: 10.1056/NEJMe0806335. [DOI] [PubMed] [Google Scholar]
- 33.Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med. 2008 Sep 25;359(13):1317–1329. doi: 10.1056/NEJMoa0804656. [DOI] [PubMed] [Google Scholar]
- 34.Schwamm L, Fayad P, Acker JE, III, et al. Translating Evidence Into Practice: A Decade of Efforts by the American Heart Association/American Stroke Association to Reduce Death and Disability Due to Stroke. A Presidential Advisory From the American Heart Association/American Stroke Association. Stroke. 2010 Feb 24; doi: 10.1161/STR.0b013e3181d2da7d. STR.0b013e3181d3182da3187d. [DOI] [PubMed] [Google Scholar]
- 35.Coe LJ, OMJ, Kunches L, Reinhalter N, Schwamm LH QCOR. An interactive training based data audit approach improves subsequent data validation in a large state-based registry 2011 [Google Scholar]